Saitoh Y, Nagao N, O'Uchida R, Yamane T, Kageyama K, Muto N, Miwa N
Department of Cell Biochemistry, Hiroshima Prefectural University School of BioScience, Shobara, Japan.
Mol Cell Biochem. 1997 Aug;173(1-2):43-50. doi: 10.1023/a:1006879001316.
Uptake of L-[1-(14)C]ascorbic acid (Asc) of 12.5-200 microM for 1 h into bovine aortic endothelial BAE-2 cells grown to confluence was as low as 43-64% (per cell) of uptake into the cells grown to nearly one-fourth confluence. [14C]Asc undergoing transmembrane uptake was concentrated and accumulated in the cell less efficiently ([Asc]in/ex = 8-13) at confluence than at subconfluence ([Asc]in/ex = 15-24). The declined Asc uptake at confluence is attributable to slowdown of the cell cycle, because a similar decrease in [Asc]in/ex was shown by subconfluent cells precultured in serum-insufficient medium, resulting in an increase in G1 phase and concurrent decreases in S and G2 + M phase distributions as determined by flow cytometry. [1-(14)C]Dehydroascorbic acid (DehAsc) was taken up and accumulated as Asc, after metabolic reduction, without detectable DehAsc. The [Asc]in/ex values for DehAsc at confluence were as low as 15-69% of those at subconfluence in contrast to the values as retentive as 62-75% for Asc, suggesting the moderate control of Asc uptake against slowdown of the cell cycle. At either confluence or subconfluence, dose-dependence for DehAsc uptake was more marked than for Asc uptake as shown by an uphill slope in a curve of doses versus [Asc]in/ex for DehAsc in contrast to a downhill slope for Asc, suggesting the moderate control for Asc uptake against fluctuation of the dose. Increasing of coexistent glucose of 5 mM to 20-40 mM, plasma concentrations in diabetic patients, declined DehAsc uptake to 46-48%, which was less moderately controlled than Asc uptake retained to 59-73%. Asc uptake did not compete with DehAsc uptake, suggesting different transporter proteins for Asc and DehAsc. Thus, Asc uptake into the aortic endothelial cells is more moderately controlled against slowdown of the cell cycle, decreasing of the extracellular concentrations or increasing of coexistent glucose than DehAsc uptake, suggesting a homeostatic advantage of Asc over DehAsc in terms of retention of intracellular Asc contents within a definite range.
将12.5 - 200微摩尔的L-[1-(14)C]抗坏血酸(Asc)摄取1小时,进入生长至汇合状态的牛主动脉内皮BAE - 2细胞的摄取量,仅为摄取到生长至近四分之一汇合状态细胞摄取量的43 - 64%( per cell)。与亚汇合状态([Asc]in/ex = 15 - 24)相比,汇合状态下经历跨膜摄取的[14C]Asc在细胞内的浓缩和积累效率较低([Asc]in/ex = 8 - 13)。汇合状态下Asc摄取量的下降归因于细胞周期的减慢,因为在血清不足的培养基中预培养的亚汇合细胞也显示出[Asc]in/ex有类似的降低,通过流式细胞术测定,这导致G1期增加,同时S期和G2 + M期分布减少。[1-(14)C]脱氢抗坏血酸(DehAsc)在代谢还原后以Asc的形式被摄取和积累,未检测到DehAsc。汇合状态下DehAsc的[Asc]in/ex值仅为亚汇合状态下的15 - 69%,而Asc的该值保持在62 - 75%,这表明在细胞周期减慢时,Asc摄取受到适度控制。在汇合状态或亚汇合状态下,DehAsc摄取的剂量依赖性比Asc摄取更明显,与Asc摄取曲线的下坡斜率相反,DehAsc的剂量与[Asc]in/ex曲线呈上升斜率,这表明在剂量波动时,Asc摄取受到适度控制。将共存葡萄糖从5毫摩尔增加到20 - 40毫摩尔(糖尿病患者的血浆浓度),使DehAsc摄取量下降至46 - 48%,其控制程度不如Asc摄取量,后者保持在59 - 73%。Asc摄取不与DehAsc摄取竞争,表明Asc和DehAsc有不同的转运蛋白。因此,与DehAsc摄取相比,主动脉内皮细胞对Asc的摄取在细胞周期减慢、细胞外浓度降低或共存葡萄糖增加时受到更适度的控制,这表明在将细胞内Asc含量保持在一定范围内方面,Asc比DehAsc具有稳态优势。